Article Text

Download PDFPDF
Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In postmenopausal women with low bone mineral density (BMD) who had been receiving daily alendronate for a mean of 5 years, what is the effect of continuing alendronate treatment for 5 years compared with discontinuing it?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Endocrine ★★★★★★☆ Rheumatology ★★★★★★☆ Internal medicine ★★★★★☆☆ Surgery—orthopaedics ★★★★★☆☆


Embedded ImageDesign:

randomised placebo controlled trial (Fracture Intervention Trial [FIT] Long-term Extension [FLEX]).

Embedded ImageAllocation:

unclear allocation concealment.*

Embedded ImageBlinding:

blinded (clinicians, participants, data collectors, and outcome assessors).*

Embedded ImageFollow up period:

5 years.

Embedded ImageSetting:

10 clinical centres in the US.

Embedded ImagePatients:

1099 postmenopausal women (mean age 73 y, 97% white) who had had low femoral neck BMD (<0.68 g/cm2) and had been allocated to alendronate (5 mg/d for 2 y and 10 …

View Full Text


  • * See glossary.

  • For correspondence: Dr D M Black, University of California, San Francisco, CA, USA. dblack{at}

  • Source of funding: Merck & Co.